Integrating HIV and hEART health in South Africa (iHeart-SA)

在南非整合艾滋病毒和心脏抗逆转录病毒治疗 (iHeart-SA)

• 批准号: 10841100
• 负责人: Mohammed Kumail Ali
• 金额: $ 30万
• 依托单位: WITS HEALTH CONSORTIUM (PTY), LTD
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-25 至 2025-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10841100
• 关键词: Address; Adoption; Blood Pressure; Cardiac health; Cardiovascular Diseases; Caring; Clinic; Communities; Country; Diabetes Mellitus; Diagnosis; Disease; Doctor of Philosophy; Documentation; Effectiveness; Evidence based intervention; Feedback; Goals; Government; Guidelines; HIV; Health care facility; Home; Hypertension; India; Institution; Intervention; Measures; Methods; Modification; Monitor; Motivation; National Heart, Lung, and Blood Institute; Output; Ownership; Patients; Persons; Provider; Publications; Randomized, Controlled Trials; Research Methodology; Review Literature; Risk; Risk Factors; Self Management; Site; South Africa; Stroke; Testing; Training; antiretroviral therapy; cluster trial; comorbidity; cost; design; experience; heart disease risk; human centered design; hypertension control; implementation science; improved; innovation; meetings; multidisciplinary; next generation; pandemic disease; patient-level barriers; primary outcome; programs; provider-level barriers; rural health clinic; scale up; screening; success; support tools; system-level barriers; treatment strategy

ABSTRACT Our multidisciplinary, multi-country team of implementation science experts propose to adapt, implement, and evaluate the “Integrating HIV and hEART health in South Africa” (iHeart-SA) program that incorporates hypertension (HTN) and diabetes (DM) screening and treatment for people living with HIV (PLWH). SA is the epicenter of the HIV pandemic worldwide with over 7 million PLWH, of whom ~5 million are treated with anti- retroviral therapies (ART). ART rollout has two relevant repercussions: first, PLWH now have approximately twice the risk of developing HTN, DM, and cardiovascular disease (CVD); and second, the success of ART programs creates a corresponding mandate to deliver integrated, high-quality, sustainable treatment strategies to detect, treat, and control HTN and DM in HIV care. There are patient-, provider-, and system-level barriers to achieving these goals; but, there are also evidence-based interventions to address them, and we have extensive experience applying these to transform care for CVD co-morbidities in South Africa and India. We have determined the barriers to CVD care and reviewed the literature to select a package of interventions proven successful in randomized controlled trials, including: use of non-clinician care coordinators to support treatment documentation and quality improvement (QI); incorporation of home monitoring to enhance self- management; decision-support tools to facilitate treatment initiation and modifications; and monthly audit / feedback meetings to support continuous QI. We will use the EPIS framework and partner with government, academic, facility, and community stakeholders to guide the project by: Exploring (engaging stakeholders in human-centered design to co-adapt the intervention package to align with local capacity, opportunities, and motivations, Aim UG1); Preparing (strengthening capacity in implementation science, Aim UG2); Implementing and evaluating the intervention package via a stepped wedge cluster trial and assessing both implementation (e.g., reach, adoption, fidelity) and effectiveness (e.g., controlled blood pressure [primary outcome] among PLWH and HTN), Aim UH1; measuring Sustainability and costs after 24 months (where 12 months were spent transferring delivery from study to local staff (Aim UH2); and developing a strategy to scale up to rural clinics and nationally (Aim UH3). The overall goal of this project is to employ rigorous empirical methods to develop and test care innovations that expand the scope of HIV care in a sustainable, scalable, and impactful way. We will employ an achievable milestone plan to deliver high quality outputs, including: continued stakeholder relationships and co-ownership of the study over the project period; completion of three PhDs in implementation science; and disseminating findings via high-impact publications and presentations. We will also participate in NHLBI’s collaborative multi-institution network designed to strengthen research methods and impacts across all sites, and to advance training of the next generation of scientific leaders.

摘要

项目成果

Comparative performance of cardiovascular risk prediction models in people living with HIV.

心血管风险预测模型在艾滋病毒患者中的比较表现。

• DOI: 10.4102/sajhivmed.v23i1.1395
• 发表时间: 2022
• 期刊: SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE
• 影响因子: 1.7
• 作者: Tahir, Irtiza S.;Vos, Alinda G.;Damen, Johanna A. A.;Barth, Roos E.;Tempelman, Hugo A.;Grobbee, Diederick E.;Scheuermaier, Karine;Venter, Willem D. F.;Klipstein-Grobusch, Kerstin
• 通讯作者: Klipstein-Grobusch, Kerstin

Weight gain stopping/switch rules for antiretroviral clinical trials.

抗逆转录病毒临床试验的体重增加停止/转换规则。

• DOI: 10.1097/qad.0000000000003221
• 发表时间: 2022
• 期刊: AIDS (London, England)
• 作者: Kouamou,Vinie;Inzaule,Seth;Manasa,Justen
• 通讯作者: Manasa,Justen